article · European Journal of Gastroenterology & Hepatology

Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients

Hany M. Elsadek
Mohamed Emara
Hanan Soliman
Elsayed S. Abdelbaser
Alaa A. Farag

20203 citationsKafr el-Sheikh University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

The risk of morbidity and mortality related to SOF/DCV ± RBV therapy in CHC patients is small and is significantly linked to advanced cirrhosis.

Research topics

Hepatitis C virus research
Liver Disease Diagnosis and Treatment
Hepatitis B Virus Studies

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1097/meg.0000000000001695

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.